The National Institute for Health and Clinical Excellence has recommended that bevacizumab, sorafenib, sunitinib and temsirolimus should not be treatment options for advanced or metastatic renal cell carcinoma.
The initial decision, which is subject to further consultation, was criticised by groups including Cancer Research UK.
See the NICE consultation documents at www.nice.org.uk
An HSJ and Novartis roundtable discussed that “best value biologics” actually means successfully creating value across the whole health and social care system – not merely assessing the comparative cost of drugs
Dr Beth Fylan on how “props and bridges” used by staff and patients promote the NHS’s safe functioning – despite the pressure borne from busy ward environments, multiple discharges and complicated medicines
Regulators and policymakers are at a loss for how to stop people accessing dangerous medicines using online services overseas, the outgoing chief inspector of GPs has said.
We are aware that some of our users are experiencing problems accessing hsj.co.uk.
To protect your security as hsj.co.uk upgrades to a new platform, your existing password will no longer work.
Financial penalties are being lifted from high-profile standards including cancer and elective waiting times, so far without attracting much attention. How is this happening? And will it work, asks Rob Findlay
No comments yet